Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM): Jagsonpal Pharmaceuticals Share Price Rises 13.8% Today

Jagsonpal Pharmaceuticals Share Price rises 13.8% to Rs 262.3, with a market cap of Rs 1,519.67 crore.

Jagsonpal Pharmaceuticals Share Price has experienced a significant rise today, closing at Rs 262.3, marking a 13.8% increase from the previous close of Rs 230.5. This notable price movement places the company's market capitalisation at Rs 1,519.67 crore. The day's trading saw the stock open at Rs 235.95, reaching a high of Rs 263, and a low of Rs 235.95, with a total turnover of Rs 4.15 crore. Despite

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 262.3
Previous Close	Rs 230.5
Today's Change	+Rs 31.8 (+13.8%)
Day Open	Rs 235.95
Day High	Rs 263
Day Low	Rs 235.95
Current Volume (BSE)	1,58,245
BSE Traded Volume	1,58,245
NSE Traded Volume	20,47,493
Combined NSE + BSE Volume	22,05,738
Turnover	Rs 4.15 crore
Market Capitalisation	Rs 1,519.67 crore
Market Cap Category	Small Cap

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) traded at Rs 262.3. versus the previous close of Rs 230.5, a rise of 13.8%. The stock opened at Rs 235.95, reached Rs 263, touched Rs 235.95. Reported volume was 1,58,245.

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,519.67 crore
P/E Ratio	33.42x
P/B Ratio	6.4x
ROE	15.7%
ROCE	19.43%
EPS	Rs 6.9
Dividend Yield	1.74%

Jagsonpal Pharmaceuticals Ltd. was valued at a P/E ratio of 33.42x, a P/B ratio of 6.4x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 15.7% and ROCE of 19.43%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 6.9, dividend yield of 1.74%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Jagsonpal Pharmaceuticals, with a market capitalisation of Rs 1,519.67 crore, operates within the Healthcare sector, specifically in Pharmaceuticals & Drugs. The company's P/E ratio stands at 33.42, which is above the industry median of 26.56 but below the average of 80.39, suggesting a relatively moderate valuation. The P/B ratio is 6.4, significantly higher than the industry median of 1.81, indicating a premium valuation. The company's ROE is 15.7%, above the industry median of 9.91%, and ROCE is 19.43%, also above the industry median of 12.96%, reflecting efficient capital use. The EPS is Rs 6.9, and the dividend yield is 1.74%, providing a modest income stream for investors. These fundamentals suggest that while the stock is priced at a premium, it offers strong profitability metrics.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	33.42x
Benchmark Median P/E	26.56x
Benchmark Average P/E	80.39x
Benchmark P/E Range	3.47x to 3,385.56x
Company P/B Ratio	6.4x
Benchmark Median P/B	1.81x
Company ROE	15.7%
Benchmark Median ROE	9.91%
Company ROCE	19.43%
Benchmark Median ROCE	12.96%
Company Market Capitalisation	Rs 1,519.67 crore
Benchmark Median Market Cap	Rs 146.72 crore

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) has a P/E ratio of 33.42x, which is above the benchmark median of 26.56x, a difference of +25.83%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) has a ROE of 15.7%, which is above the benchmark median of 9.91%, a difference of +58.43%. Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) has a ROCE of 19.43%, which is above the benchmark median of 12.96%, a difference of +49.92%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Jagsonpal Pharmaceuticals operates in the Healthcare sector, specifically within the Pharmaceuticals & Drugs industry. The sector comprises 137 companies, with Jagsonpal's P/E ratio of 33.42 positioned above the industry median of 26.56 but below the average of 80.39. The company's P/B ratio of 6.4 is significantly higher than the industry median of 1.81, indicating a premium valuation. In terms of profitability, Jagsonpal's ROE of 15.7% and ROCE of 19.43% are both above the industry medians, highlighting its strong financial performance. The sector's market capitalisation ranges from Rs 6.44 crore to Rs 2,856.59 crore, with Jagsonpal positioned as a small-cap player. This context underscores the company's competitive positioning within its industry.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,856.59	30.28	0.44	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,686.76	40.11	8.17	28.21	26.35
Hikal Ltd.	HIKAL	2,676.24	0	2.27	15.22	16.15
Panacea Biotec Ltd.	PANACEABIO	2,540.37	0	3.11	0	5.36
Solara Active Pharma Sciences Ltd.	SOLARA	2,446.19	0	1.91	17.23	15.34

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) has a P/E ratio of 33.42x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 15.7% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 19.43% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) has a market capitalisation of Rs 1,519.67 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

In comparison to its peers, Jagsonpal Pharmaceuticals exhibits a competitive edge in several financial metrics. While its P/E ratio of 33.42 is higher than Dishman Carbogen Amcis Ltd. (30.28) and lower than Kwality Pharmaceuticals Ltd. (40.11), it remains within a competitive range. The company's ROE of 15.7% surpasses that of Hikal Ltd. (15.22) and is comparable to Solara Active Pharma Sciences Ltd. (17.23). Jagsonpal's ROCE of 19.43% is higher than Panacea Biotec Ltd. (5.36) and aligns closely with Beta Drugs Ltd. (22.17). These comparisons highlight Jagsonpal's strong profitability and market positioning relative to its peers.

Why Investors Are Watching Jagsonpal Pharmaceuticals

Investors are closely monitoring Jagsonpal Pharmaceuticals due to its significant price rise and strong financial metrics.

• Price Action: The stock rose 13.8% today, surpassing the small-cap threshold.
• Technical Position: Trading above key moving averages with neutral RSI.
• Fundamental Context: Strong ROE and ROCE, premium valuation.
• Sector Positioning: Competitive within the Pharmaceuticals & Drugs industry.

Investors should continue to monitor Jagsonpal Pharmaceuticals for further developments in its financial performance and market activity.

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Ltd. is a prominent player in the Healthcare sector, focusing on the Pharmaceuticals & Drugs industry. The company is engaged in the development, manufacture, and marketing of pharmaceutical products, catering to various therapeutic segments. With a strong emphasis on research and development, Jagsonpal Pharmaceuticals aims to deliver high-quality and innovative healthcare solutions. The company's diverse product portfolio and strategic market positioning enable it to address the evolving needs of the healthcare industry. As a small-cap entity, Jagsonpal Pharmaceuticals continues to leverage its expertise to enhance its market presence and drive growth.

Track Jagsonpal Pharmaceuticals Share Price on Univest

Use Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors can track Jagsonpal Pharmaceuticals Share Price on Univest for real-time updates on share price, technical indicators, fundamental ratios, and market insights. Univest provides comprehensive data, including 52-week levels and shareholding patterns, to help investors make informed decisions. Stay updated with the latest market trends and financial analysis on Univest.

Frequently Asked Questions

What is the current share price of Jagsonpal Pharmaceuticals?

Ans. The current share price of Jagsonpal Pharmaceuticals is Rs 262.3, reflecting a 13.8% increase from the previous close of Rs 230.5. The stock moved 13.8% during the session. The intraday range extended from Rs 235.95 to Rs 263.

How much did Jagsonpal Pharmaceuticals' share price rise today?

Ans. Jagsonpal Pharmaceuticals' share price rose by 13.8% today, closing at Rs 262.3, up from the previous close of Rs 230.5. The stock moved 13.8% during the session. The intraday range extended from Rs 235.95 to Rs 263.

What is the market capitalisation of Jagsonpal Pharmaceuticals?

Ans. Jagsonpal Pharmaceuticals has a market capitalisation of Rs 1,519.67 crore, categorising it as a small-cap company in the Healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 33.42x.

How does Jagsonpal Pharmaceuticals compare to its peers?

Ans. Jagsonpal Pharmaceuticals' P/E, ROE, and ROCE are competitive within its peer group, highlighting its strong market positioning. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Hikal Ltd.

What is the P/E ratio of Jagsonpal Pharmaceuticals?

Ans. The P/E ratio of Jagsonpal Pharmaceuticals is 33.42, which is above the industry median but below the average, indicating a moderate valuation. The company trades at a P/E ratio of 33.42x.

How can I track Jagsonpal Pharmaceuticals' share price?

Ans. Investors can track Jagsonpal Pharmaceuticals' share price and market insights on Univest for real-time updates and comprehensive data analysis. The stock moved 13.8% during the session. The intraday range extended from Rs 235.95 to Rs 263.